Channel Medsystems announced today that long-term clinical outcomes support its Cerene cryotherapy for treating heavy menstrual bleeding (HMB).
Long-term outcomes from the Clarity clinical study evaluating the safety and effectiveness of Cerene cryotherapy were published in the International Journal of Women’s Health.
Emeryville, California-based Channel Medsystems designed Cerene as a proprietary, hand-held technology for delivering cryotherapy to the lining of the uterus, freezing the tissue and significantly reducing future menstrual bleeding. The company received FDA approval for the platform in 2020.
The in-office endometrial cryoablation treatment safely and effectively reduces heavy menstrual bleeding while naturally minimizing pain without requiring general anesthesia, the company said in a news release.
In the study, Cerene is presented as a well-tolerated endometrial ablation that provides a significant reduction in HMB symptoms an…